Skip to main content
. Author manuscript; available in PMC: 2021 Sep 20.
Published in final edited form as: Gynecol Oncol. 2020 Aug 26;159(1):101–111. doi: 10.1016/j.ygyno.2020.05.045

Fig. 4.

Fig. 4.

Forest plot of relative risk of most frequent any grade TEAEs (≥35% of patients. in any age subgroup) and grade ≥3 TEAEs. aCombined AST elevation and ALT elevation. bCombined anemia and decreased hemoglobin. cCombined asthenia and fatigue. dCombined thrombocytopenia and decreased platelet count. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; TEAEs, treatment-emergent adverse events.